- Home
- »
- Biotechnology
- »
-
Biopharmaceuticals Contract Manufacturing Market Report 2033GVR Report cover
Biopharmaceuticals Contract Manufacturing Market (2026 - 2033)
Size, Share & Trends Analysis Report By Source (Mammalian, Non-mammalian), By Service, By Drug Type (Biologics, Biosimilars), By Type, By Scale Of Operation (Clinical, Commercial), By Therapeutic Area, By Region, And Segment Forecasts
Market Size, 2025
$44.7BMarket Estimate, 2026
$50.0BMarket Forecast, 2033
$100.8BCAGR, 2026–2033
10.5%Biopharmaceuticals Contract Manufacturing Market Summary
The global biopharmaceuticals contract manufacturing market size was valued at USD 44.7 billion in 2025 and is projected to grow from USD 50.0 billion in 2026 to USD 100.8 billion by 2033, at a CAGR of 10.5% from 2026 to 2033. North America dominated the market with the revenue share of 34.6% in 2025. The biopharmaceutical contract manufacturing market is anticipated to grow over the forecast period owing to the expanding biologics pipeline, increasing outsourcing by pharmaceutical and biotechnology companies, rising demand for monoclonal antibodies and biosimilars, growing commercial manufacturing requirements for biologics, and continuous investments in global biopharmaceutical manufacturing capacity.
Source: Grand View Research, IR Documents, Primary Interviews, Paid DatabasesTo learn more about this report,
Download Free Sample Report Key Market Trends & Insights
- By source: Mammalian segment led the market with the largest revenue share of 58.9% in 2025.
- By service: Process development segment led the market with the largest revenue share of 34.7% in 2025.
- By drug type: Biologics segment led the market with the largest revenue share of 78.1% in 2025.
- By type: Drug substance segment led the market with the largest revenue share of 57.6% in 2025.
- By scale of operation: Commercial segment led the market with the largest revenue share of 75.1% in 2025.
Regional Highlights
- Largest regional market: North America (34.6% revenue share, 2025)
- Fastest-growing regional market: Asia Pacific (highest CAGR, 2026-2033)
- By country: The U.S. held the largest market share in 2025.
Market Size & Forecast
- Market Size in 2025: USD 44.7 Billion
- Estimated market size in 2026: USD 50.0 Billion
- Projected market size by 2033: USD 100.8 Billion
- CAGR (2026-2033): 10.5%
Three ways to get this report
Buy it, customize it, or ask a question.Ask an Analyst
Analyst response in 1 business day
- AccessReport author, directly
- Reply timeWithin 1 working day
- No sales callDirect answer only
- FormatEmail reply
- CostFree, no cost
Get the Full Report
What the study covers
- FormatsPDF · Excel · Dashboard
- Timeline2026–2033 annual, 2025 base
- Coverage20+ countries, 5 regions
- Companies10+ key players profiled
Customize the Report
20% free customization
- IncludeCountries, segments, points
- TailorTo your product definition
- ExtendDeeper competitor detail
- OrA fully bespoke study
- Turnaround5–10 working days
The market growth is further supported by the increasing complexity of biologic manufacturing processes, stringent regulatory requirements, and the need for specialized production technologies that require substantial capital investment. These factors are encouraging drug developers to partner with contract development and manufacturing organizations for process development, clinical manufacturing, commercial production, analytical testing, and fill finish operations across multiple biologic modalities.
To learn more about this report, Download Free Sample Report The expanding biologics pipeline remains one of the primary factors driving the market. Biopharmaceuticals, including monoclonal antibodies, recombinant proteins, vaccines, and advanced biologics, require specialized manufacturing platforms, process optimization, and regulatory-compliant production facilities that many developers choose to outsource. The growing number of biologic products advancing through clinical development is increasing demand for contract manufacturing services across both clinical and commercial stages. For instance, in May 2025, FUJIFILM Diosynth Biotechnologies announced a USD 3.2 billion expansion of its Holly Springs, North Carolina, facility to increase large-scale biologics manufacturing capacity, supporting the rising global demand for commercial production of monoclonal antibodies and other biologic therapies.
The increasing outsourcing of biologic manufacturing is another major driver supporting market expansion. The construction and qualification of biopharmaceutical manufacturing facilities require substantial investment in single-use technologies, bioreactor infrastructure, quality systems, and regulatory compliance, making outsourcing a preferred strategy for many pharmaceutical and biotechnology companies. Furthermore, contract manufacturers offer integrated capabilities from cell line development through commercial fill-and-finish, enabling faster development timelines and greater operational flexibility. The rising outsourcing demand is encouraging leading contract manufacturers to expand commercial manufacturing capacity and establish specialized facilities for diverse biologic modalities. These investments are intended to address growing customer requirements for integrated development and manufacturing services while supporting large-scale commercial production. For instance, in June 2025, WuXi Biologics announced the new microbial manufacturing site in Chengdu's Wenjiang district, China, comprising dedicated drug substance and drug product facilities for commercial manufacturing. The site will support the production of peptides, antibody fragments, plasmid DNA, enzymes, cytokines, and virus-like particles, with an annual drug product manufacturing capacity exceeding 10 million vials, strengthening the company's commercial biologics manufacturing capabilities.
The market growth is driven by high capital investment requirements, complex technology transfer processes, lengthy regulatory qualification timelines, and limited availability of specialized biologics manufacturing expertise. The increasing commercialization of biosimilars, the expansion of cell and gene therapy manufacturing, the growing development of biologics among emerging biotechnology companies, and continued investments in advanced manufacturing technologies are expected to create substantial opportunities for contract manufacturing organizations over the forecast period. Thus, the increasing global demand for biologic therapies, together with continued outsourcing across clinical and commercial manufacturing, is expected to support the sustained growth of the biopharmaceutical contract manufacturing market.
Market Dynamics
The increasing outsourcing of biopharmaceutical manufacturing is one of the key drivers of the biopharmaceutical contract manufacturing market's growth. The development and production of biologics require specialized manufacturing technologies, advanced process development capabilities, and compliance with stringent regulatory standards, making in-house manufacturing capital-intensive and operationally complex. Pharmaceutical and biotechnology companies are increasingly partnering with contract development and manufacturing organizations to access established manufacturing infrastructure, technical expertise, and integrated services spanning cell line development, process optimization, analytical testing, drug substance production, and commercial fill-and-finish. The growing number of emerging biotechnology companies with limited manufacturing capabilities and the need to accelerate product development timelines are further increasing outsourcing activity, encouraging contract manufacturers to expand manufacturing capacity and strengthen end-to-end service offerings.
High capital investment requirements and complex technology transfer processes remain key restraints for the biopharmaceutical contract manufacturing market. The establishment of biologics manufacturing facilities requires substantial expenditure on bioreactors, single-use systems, cleanrooms, analytical laboratories, quality management systems, and regulatory-compliant infrastructure. In addition, transferring manufacturing processes from sponsors to contract manufacturers involves extensive process validation, comparability studies, analytical method qualification, and regulatory documentation to maintain product quality and consistency. Variability in biologic production processes, together with stringent Good Manufacturing Practice requirements and regulatory inspections, can extend project timelines and increase operational costs. These factors may delay manufacturing readiness and limit expansion opportunities for smaller contract manufacturers and emerging biotechnology companies.
The expanding commercialization of biosimilars presents a major opportunity for the biopharmaceutical contract manufacturing market. Patent expirations for several high-value biologics and rising regulatory approvals in major markets are encouraging pharmaceutical companies to accelerate biosimilar development and commercialization. Many biosimilar developers seek contract manufacturing partners with expertise in cell culture, process development, analytical characterization, scale-up, and commercial manufacturing to reduce development costs and improve time to market. The increasing demand for cost-effective biologic therapies across developed and emerging healthcare markets is expected to generate sustained demand for contract manufacturing services. Furthermore, continued investments in large-scale biologics manufacturing capacity, advanced bioprocessing technologies, and integrated development services are expected to strengthen the ability of contract manufacturers to support the growing global biosimilars market.
Market Concentration & Characteristics
The biopharmaceuticals contract manufacturing market growth stage is moderate, and growth is accelerating. The market is characterized by the degree of innovation, level of M&A activities, regulatory impact, service expansion, and regional expansion.
Innovation remains a key competitive factor in the biopharmaceutical contract manufacturing market, with contract manufacturers investing in advanced bioprocessing technologies, single use manufacturing systems, continuous bioprocessing, automation, and digital manufacturing platforms. The increasing demand for biologics, biosimilars, monoclonal antibodies, and other complex biologic products is encouraging the adoption of advanced manufacturing and analytical technologies that improve process efficiency, product quality, and production flexibility. Continued technological advancements enable contract manufacturers to improve manufacturing scalability, reduce development timelines, and strengthen regulatory compliance across clinical and commercial production.
To learn more about this report, Download Free Sample Report Mergers and acquisitions continue to shape the biopharmaceutical contract manufacturing market by expanding manufacturing capacity, strengthening biologics development capabilities, and broadening integrated service offerings. Strategic acquisitions enable contract development and manufacturing organizations to enhance expertise in cell line development, upstream and downstream processing, analytical testing, fill and finish operations, and commercial biologics manufacturing while expanding their global manufacturing footprint. These transactions also improve production capacity, diversify customer portfolios, and strengthen competitive positioning within the global biopharmaceutical outsourcing industry.
Regulatory compliance remains a major factor influencing the biopharmaceutical contract manufacturing market. Manufacturers are required to comply with current Good Manufacturing Practice standards, International Council for Harmonisation guidelines, regulatory requirements established by agencies such as the U.S. Food and Drug Administration and the European Medicines Agency, and comprehensive quality management systems governing biologics production. Compliance with stringent validation, process control, documentation, sterility assurance, and product quality requirements increases operational complexity while providing competitive advantages for manufacturers with established regulatory expertise and proven inspection records.
Biopharmaceutical contract manufacturers are expanding their service portfolios to provide integrated development and manufacturing solutions across the biologics product lifecycle. Many contract development and manufacturing organizations now offer cell line development, process development, analytical testing, formulation development, drug substance manufacturing, fill and finish, technology transfer, regulatory support, and commercial manufacturing through a single platform. Integrated service offerings improve operational efficiency, simplify outsourcing management, and enable pharmaceutical and biotechnology companies to accelerate biologics development and commercialization.
Regional expansion continues to strengthen the global presence of biopharmaceutical contract manufacturers. Companies are establishing new biologics manufacturing facilities and expanding existing production sites across North America, Europe, and the Asia Pacific to meet the growing demand for clinical and commercial biologics. Geographic expansion improves manufacturing capacity, strengthens supply chain resilience, supports regional regulatory requirements, and enables contract manufacturers to provide localized manufacturing services while serving a growing global customer base.
Analyst Perspective
The biopharmaceutical contract manufacturing market is witnessing strong growth, driven by the expanding biologics pipeline, increasing commercialization of monoclonal antibodies, recombinant proteins, biosimilars, and vaccines, and rising outsourcing by pharmaceutical and biotechnology companies. The growing complexity of biologics manufacturing and stringent regulatory requirements are increasing demand for integrated contract manufacturing services spanning cell line development through commercial production. Companies offering integrated service platforms, advanced manufacturing technologies, and strong regulatory expertise are expected to strengthen their market position and support sustained market growth.
Impact of U.S. Tariffs on the Global Biopharmaceuticals Contract Manufacturing Market
The implementation of U.S. tariffs on selected imported laboratory equipment, bioprocessing systems, specialty chemicals, stainless steel components, and manufacturing equipment has increased capital and operating costs for biopharmaceutical contract manufacturers. Higher procurement costs for bioreactors, filtration systems, chromatography equipment, single-use technologies, and critical manufacturing components have increased investment requirements for facility expansion and capacity upgrades. Contract manufacturers with global supply chains may also experience procurement delays and higher sourcing costs for raw materials and production equipment, which can affect manufacturing schedules and project execution.
Biopharmaceutical companies may incur higher outsourcing costs for clinical and commercial manufacturing programs, particularly for complex biologics that require advanced manufacturing infrastructure and specialized production technologies. Many contract manufacturers are expanding regional supplier networks, increasing local procurement of manufacturing components, and strengthening inventory management to improve supply continuity and reduce exposure to tariff-related disruptions. Equipment suppliers are also expanding manufacturing and servicing capabilities across major biopharmaceutical hubs to improve equipment availability.
Demand for biopharmaceutical contract manufacturing services remains strong, supported by the expanding biologics pipeline, the increasing commercialization of biosimilars, and continued outsourcing by pharmaceutical and biotechnology companies. Long-term manufacturing agreements, investments in regional production capacity, and the development of localized supply chains are expected to reduce the impact of higher input costs over time. These developments are likely to improve supply chain resilience while supporting the long-term growth of the global biopharmaceutical contract manufacturing market.
Technological Advancements
Technological advancements are reshaping the biopharmaceutical contract manufacturing market by improving manufacturing efficiency, product quality, and operational flexibility across the biologics production value chain. Contract manufacturers are expanding investments in modern production platforms to improve manufacturing capacity while meeting increasingly stringent regulatory and quality requirements. The adoption of advanced manufacturing technologies is supporting faster process development, improved scale-up capabilities, and more efficient utilization of production infrastructure.
To learn more about this report, Download Free Sample Report Furthermore, digital monitoring tools and automated manufacturing systems are improving process consistency while reducing manufacturing variability and operational risks. The growing complexity of biologic products, including monoclonal antibodies, recombinant proteins, biosimilars, and emerging therapeutic modalities, is increasing the need for advanced manufacturing capabilities across both clinical and commercial production. Continued investment in innovative bioprocessing technologies is enabling contract manufacturers to expand integrated service offerings and strengthen their competitive position within the global outsourcing industry. These developments are expected to improve production capacity, accelerate commercialization timelines, and support the growing outsourcing requirements of pharmaceutical and biotechnology companies, contributing to sustained growth in the global biopharmaceutical contract manufacturing market over the forecast period.
Pricing Model Analysis
In biopharmaceutical contract manufacturing market, the pricing models adopted across the biopharmaceutical contract manufacturing market vary according to manufacturing stage, service scope, production volume, and contractual arrangements between sponsors and contract manufacturers. Pharmaceutical and biotechnology companies select pricing structures based on development timelines, manufacturing complexity, commercial objectives, and outsourcing strategy. Contract manufacturers continue to offer flexible commercial arrangements to accommodate early-stage development programs, clinical manufacturing requirements, and large-scale commercial production. Integrated manufacturing capabilities, regulatory support, quality management systems, and production capacity remain important factors influencing pricing negotiations across outsourcing agreements.
To learn more about this report, Download Free Sample Report Furthermore, increasing demand for biologics, biosimilars, and other advanced therapeutic products is encouraging greater use of long-term manufacturing partnerships that provide improved production planning and resource allocation. Manufacturing costs are also influenced by facility utilization, process efficiency, technology platforms, and product-specific requirements, leading to variation in pricing across different biologic modalities. As outsourcing activity continues to expand, pricing strategies are expected to evolve toward greater flexibility while balancing manufacturing efficiency, regulatory compliance, and long-term collaboration, supporting sustainable commercial relationships throughout the global biopharmaceutical contract manufacturing market.
Source Insights
Based on source, the mammalian segment led the market with the largest revenue share of 58.9% in 2025. This is attributed to the widespread use of mammalian cell expression systems, particularly Chinese hamster ovary (CHO) cells, for the production of monoclonal antibodies, recombinant proteins, and other complex biologics. Mammalian systems provide high protein expression, appropriate post-translational modifications, and product quality required for commercial biologics manufacturing. Increasing approvals of monoclonal antibodies and growing outsourcing of complex biologics manufacturing continue to support the dominance of this segment.
The non-mammalian segment is projected to register the fastest CAGR during the forecast period. The increasing demand for cost-effective manufacturing of recombinant proteins, vaccines, enzymes, plasmid DNA, and peptide therapeutics is encouraging the adoption of microbial and yeast-based expression systems. Faster production cycles, lower manufacturing costs, and continuous technological advancements in microbial fermentation are expected to support the growth of contract manufacturing services based on non-mammalian platforms.
Service Insights
Based on service, the process development segment led the market with the largest revenue share of 34.7% in 2025. The increasing complexity of biologics manufacturing requires extensive process optimization, cell culture development, scale-up studies, and manufacturing validation before commercial production. Pharmaceutical and biotechnology companies increasingly outsource process development activities to contract manufacturers with specialized expertise to reduce development timelines and improve manufacturing efficiency.
The analytical and QC studies segment is expected to register the fastest CAGR during the forecast period. Increasing regulatory requirements for biologics characterization, product quality, impurity profiling, comparability assessments, and stability testing are driving demand for advanced analytical services. The growing development of biosimilars and complex biologics is further increasing the need for comprehensive analytical testing throughout product development and commercial manufacturing.
Drug Type Insights
Based on drug type, the biologics segment led the market with the largest revenue share of 78.1% in 2025. The increasing commercialization of monoclonal antibodies, recombinant proteins, vaccines, and other biologic therapies has generated substantial demand for contract manufacturing services. Rising investments in biologics research, expanding clinical pipelines, and increasing outsourcing by pharmaceutical and biotechnology companies continue to support this segment's growth.
The biosimilars segment is projected to witness the fastest CAGR during the forecast period. The expiration of patents for several high-value biologics, increasing regulatory approvals, and growing demand for affordable biologic therapies are encouraging biosimilar development worldwide. Biopharmaceutical companies are increasingly partnering with contract manufacturers to access specialized manufacturing capabilities while reducing development costs and accelerating commercialization.
Type Insights
Based on type, the drug substance segment led the market with the largest revenue share of 57.6% in 2025. The increasing outsourcing of upstream and downstream manufacturing, cell culture production, purification, and process optimization is supporting strong demand for drug substance manufacturing services. Growing biologics pipelines and increasing commercial production requirements continue to strengthen the position of this segment.
The finished drug product segment is anticipated to register the fastest CAGR during the forecast period. The increasing demand for integrated outsourcing solutions encompassing formulation development, aseptic fill-and-finish, packaging, and commercial supply is prompting pharmaceutical companies to partner with contract manufacturers offering end-to-end production capabilities. Growing commercialization of biologics and biosimilars is expected to further support segment growth.
Scale of Operation Insights
Based on scale of operation, the commercial segment led the market with the largest revenue share of 75.1% in 2025. Increasing regulatory approvals of biologics, expanding commercial production volumes, and growing long-term manufacturing agreements between pharmaceutical companies and contract manufacturers are supporting sustained demand for commercial-scale manufacturing services. Capacity expansion by leading contract manufacturers further fuels this segment's growth.
The clinical segment is projected to register the fastest CAGR during the forecast period. The increasing number of biologics entering clinical development, expanding biotechnology research activities, and rising outsourcing of early phase manufacturing are driving demand for flexible clinical manufacturing services. Contract manufacturers are expanding small-scale manufacturing capabilities to support accelerated clinical development programs.
Therapeutic Area Insights
Based on therapeutic area, the oncology segment led the market with the largest revenue share of 38.3% in 2025. The increasing prevalence of cancer and the growing approvals of monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, and other targeted biologic therapies have substantially increased demand for contract manufacturing services. Continued investments in oncology, drug development, and expansion of the global oncology pipeline are expected to support the growth of this segment.
To learn more about this report, Download Free Sample Report The autoimmune diseases segment is expected to register a significant CAGR during the forecast period. The increasing prevalence of autoimmune disorders, the growing adoption of biologic therapies for chronic inflammatory diseases, and the continuous development of monoclonal antibodies and biosimilars are driving demand for contract manufacturing services. Rising healthcare expenditure and increasing patient access to advanced biologic treatments are expected to further support segment growth.
Regional Insights
North America dominated the biopharmaceuticals contract manufacturing market with the largest revenue share of 34.6% in 2025. The market is supported by a well-established biopharmaceutical industry, an expanding biologics pipeline, and increasing outsourcing by pharmaceutical and biotechnology companies. The growing commercialization of monoclonal antibodies, recombinant proteins, biosimilars, and advanced biologics is increasing demand for contract development and manufacturing services across clinical and commercial stages. The region benefits from advanced manufacturing infrastructure, strong regulatory standards, and the presence of leading global CDMOs. Continued investments in manufacturing capacity expansion and advanced bioprocessing technologies are expected to support market growth over the forecast period.
To learn more about this report, Download Free Sample Report U.S. Biopharmaceuticals Contract Manufacturing Market Trends
The biopharmaceuticals contract manufacturing market in the U.S. held the largest share in the North America region in 2025. Market growth is supported by a large biotechnology sector, rising biologics research and development, and pharmaceutical companies' increasing outsourcing of manufacturing. The presence of leading contract development and manufacturing organizations, continuous investments in large-scale biologics manufacturing facilities, and growing demand for integrated development and commercial manufacturing services are expected to support sustained market expansion.
The Canada biopharmaceuticals contract manufacturing market is expected to grow at a significant CAGR during the forecast period. The market is growing steadily owing to increasing investments in biotechnology research, expanding biologics manufacturing capabilities, and growing collaborations between pharmaceutical companies and contract manufacturers. Government support for life sciences, increased clinical development activities, and the expansion of biologics production facilities are driving demand for contract manufacturing services.
Europe Biopharmaceuticals Contract Manufacturing Market Trends
The biopharmaceuticals contract manufacturing market in Europe is experiencing steady growth, supported by a mature pharmaceutical industry, increasing biologics development, and stringent regulatory standards governing biologics manufacturing. Growing investments in biosimilars, monoclonal antibodies, recombinant proteins, and advanced therapeutic products are increasing demand for specialized development and manufacturing services. The region benefits from leading CDMOs, advanced manufacturing infrastructure, and strong research capabilities. Continued investments in manufacturing capacity and integrated service platforms are expected to support market growth throughout the forecast period.
The Germany biopharmaceutical contract manufacturing market is witnessing stable growth owing to its strong pharmaceutical manufacturing base, advanced bioprocessing capabilities, and increasing biologics production. Growing demand for biosimilars and monoclonal antibodies, together with increasing investments in manufacturing technologies and commercial production facilities, is supporting the expansion of contract manufacturing services across the country.
The biopharmaceuticals contract manufacturing market in the UK is expected to grow significantly over the forecast period. Market expansion is supported by a strong biotechnology ecosystem, increasing biologics research activities, and the presence of established pharmaceutical companies and contract manufacturers. Rising investments in biologics manufacturing, expansion of commercial production capacity, and continued government support for life sciences are expected to contribute to sustained market growth.
Asia Pacific Biopharmaceuticals Contract Manufacturing Market Trends
The biopharmaceuticals contract manufacturing market in the Asia Pacific is expected to register the fastest growth during the forecast period, driven by expanding pharmaceutical manufacturing capacity, rising biotechnology investments, and lower manufacturing costs. The growing number of biotechnology companies, increasing clinical research activities, and favorable government initiatives are encouraging pharmaceutical companies to outsource biologics manufacturing to the region. Continued investments in modern bioprocessing facilities and commercial manufacturing infrastructure are expected to strengthen the region's position in the global market.
The Japan biopharmaceutical contract manufacturing market is experiencing steady growth due to increasing biologics development, expanding biosimilars market, and strong pharmaceutical research capabilities. Growing investments in advanced manufacturing technologies and increasing outsourcing of biologics production by domestic and international pharmaceutical companies are expected to support long-term market expansion.
The biopharmaceutical contract manufacturing market in China is witnessing rapid growth, supported by expanding biotechnology investments, increasing biologics development, and large-scale manufacturing capacity expansion. The presence of leading contract manufacturers, favorable government policies supporting the biopharmaceutical industry, and increasing commercial production of biologics and biosimilars continue to strengthen the country's position as a major global manufacturing hub.
The India biopharmaceutical contract manufacturing market is expected to grow at a significant pace owing to its cost-competitive manufacturing capabilities, expanding biotechnology sector, and increasing regulatory-compliant manufacturing facilities. Growing outsourcing by global pharmaceutical companies, increasing biosimilars development, and continuous investments in biologics manufacturing infrastructure are expected to support sustained market growth.
Latin America Biopharmaceuticals Contract Manufacturing Market Trends
The biopharmaceuticals contract manufacturing market in Latin America is experiencing gradual growth, supported by increasing pharmaceutical manufacturing activities, expanding access to biologic therapies, and growing investments in biotechnology. Rising demand for biosimilars, improving healthcare infrastructure, and increasing collaborations between regional pharmaceutical companies and global contract manufacturers are expected to support market development over the forecast period.
The Brazil biopharmaceuticals contract manufacturing market accounted for the largest share in Latin America in 2025.Market growth is increasing biologics adoption, expanding domestic pharmaceutical manufacturing, and government initiatives supporting local biopharmaceutical production. Growing demand for affordable biologic therapies and increasing investments in biotechnology research are expected to strengthen contract manufacturing opportunities in the country.
Middle East & Africa Biopharmaceuticals Contract Manufacturing Market Trends
The biopharmaceuticals contract manufacturing market in the Middle East and Africa is gradually expanding, driven by rising healthcare investments, expanding pharmaceutical manufacturing, and increasing demand for biologic therapies. Government initiatives promoting domestic pharmaceutical production, improving regulatory frameworks, and increasing collaborations with international pharmaceutical companies are expected to contribute to market growth during the forecast period.
The UAE biopharmaceutical contract manufacturing market is expected to witness notable growth, driven by increasing investments in pharmaceutical manufacturing, expansion of life sciences infrastructure, and government initiatives to strengthen local pharmaceutical production. Rising demand for advanced biologic therapies, increasing partnerships with global pharmaceutical companies, and continued investment in biotechnology capabilities are expected to support the growth of contract manufacturing services in the country.
Key Biopharmaceuticals Contract Manufacturing Company Insights
The key players operating across the market are adopting strategic initiatives such as service launches, mergers & acquisitions, partnerships & agreements, and expansions to gain a competitive edge in the market. For instance, in April 2025, Regeneron Pharmaceuticals entered a more than USD 3 billion, 10-year manufacturing agreement with FUJIFILM Diosynth Biotechnologies to manufacture and supply biologic medicines from the company's Holly Springs, North Carolina facility. The agreement expands large-scale commercial biologics manufacturing capacity and strengthens long-term contract manufacturing capabilities for global biopharmaceutical production.
Key Biopharmaceuticals Contract Manufacturing Companies
The following key companies have been profiled for this study on the biopharmaceuticals contract manufacturing market.
-
Boehringer Ingelheim GmbH
-
Lonza
-
Inno Biologics Sdn Bhd
-
Rentschler Biotechnologie GmbH
-
JRS PHARMA
-
AGC Biologics
-
ProBioGen
-
FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
-
Toyobo Co. Ltd.
-
Samsung Biologics
-
Thermo Fisher Scientific, Inc.
-
Binex Co., Ltd.
-
WuXi Biologics
-
AbbVie, Inc.
-
ADMA Biologics, Inc.
-
Catalent, Inc
-
Cambrex Corporation
-
Pfizer Inc.
-
Siegfried Holding AG
Competitive Benchmarking
Operating Strategies
Competitive Edge
Weaknesses
Established Players (Lonza, Samsung Biologics)
- Established companies focus on expanding large-scale biologics manufacturing capacity across mammalian and microbial platforms while offering integrated contract development and manufacturing services.
- Their portfolios typically include cell line development, process development, analytical testing, drug substance manufacturing, fill-and-finish, regulatory support, and commercial production.
- Continuous investments in advanced bioprocessing technologies, digital manufacturing, and global manufacturing networks strengthen their ability to serve multinational pharmaceutical and biotechnology companies.
- Established players benefit from extensive global manufacturing infrastructure, diversified technology platforms, strong regulatory compliance records, and broad expertise across multiple biologic modalities.
- Their ability to support projects from early development through commercial manufacturing, along with long-standing customer relationships and proven manufacturing capabilities, enables them to secure large-scale, long-term outsourcing agreements.
- Established companies face high capital expenditure associated with biologics manufacturing facilities, continuous investments in technology upgrades, and increasing operational costs.
- Large organizational structures may also reduce manufacturing flexibility and extend project onboarding timelines, particularly for early-stage biotechnology companies requiring rapid manufacturing support.
Emerging Players (WuXi Biologics)
- Emerging companies primarily focus on specialized biologics manufacturing capabilities, flexible manufacturing platforms, and integrated development services for biotechnology companies.
- Many continue to expand clinical and commercial manufacturing capacity while investing in advanced cell culture technologies, microbial manufacturing, analytical capabilities, and process optimization to strengthen their market position.
- Emerging players benefit from operational flexibility, faster project execution, specialized technical expertise, and customized manufacturing solutions.
- Their ability to provide dedicated development support, competitive manufacturing costs, and rapid technology transfer enables them to attract emerging biotechnology companies and innovative biologics developers.
- Emerging companies often face limitations in global manufacturing footprint, commercial production capacity, and financial resources for large scale facility expansion.
- Limited presence across multiple regulatory markets and increasing competition from established global contract development and manufacturing organizations may restrict long-term market expansion and large commercial contract opportunities.
Recent Developments
-
In May 2025, PCI Pharma Services completed the acquisition of Ajinomoto Althea, a U.S.-based sterile fill finish CDMO, as part of its USD 1 billion investment strategy. The acquisition expands PCI's drug product manufacturing capabilities in North America by adding large-scale aseptic fill-finish capacity for prefilled syringes and cartridges, including isolator technology and manufacturing capabilities for complex biologics such as monoclonal antibodies, proteins, mRNA, oligonucleotides, peptides, nanoparticles, and antibody drug conjugates.
-
In January 2025, Boehringer Ingelheim entered a licensing agreement with Synaffix to access antibody drug conjugate technology, strengthening its oncology development pipeline and increasing future demand for specialized biologics development and manufacturing capabilities.
Biopharmaceuticals Contract Manufacturing Market Report Scope
Report Attribute
Details
Market size value in 2025
USD 44.7 billion
Market size value in 2026
USD 50.0 billion
Revenue forecast in 2033
USD 100.8 billion
Growth rate
CAGR of 10.5% from 2026 to 2033
Actual Data
2021 - 2025
Forecast period
2026 - 2033
Quantitative units
Revenue in USD billion and CAGR from 2026 to 2033
Report coverage
Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments covered
Source, service, drug type, type, scale of operation, therapeutic area, region
Regional scope
North America, Europe, Asia Pacific, Latin America, MEA
Country scope
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Norway; Denmark; Sweden; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; Saudi Arabia; South Africa; UAE; Kuwait; Oman; Qatar.
Key companies profiled
Boehringer Ingelheim GmbH; Lonza; Inno Biologics Sdn Bhd; Rentschler Biotechnologie GmbH; JRS Pharma; AGC Biologics; ProBioGen; Fujifilm Diosynth Biotechnologies U.S.A.; Inc.; Toyobo Co.; Ltd.; Samsung BioLogics; Thermo Fisher Scientific, Inc.; Binex Co., Ltd.; WuXi Biologics; AbbVie, Inc; ADMA Biologics, Inc.; Catalent, Inc; Cambrex Corporation; Pfizer Inc.; Siegfried Holding AG, among others.
Customization scope
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options
Avail customized purchase options to meet your exact research needs. Explore purchase options
Global Biopharmaceuticals Contract Manufacturing Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceuticals contract manufacturing market report based on source, service, drug type, type, scale of operation, therapeutic area, and region:
-
Source Outlook (Revenue, USD Billion, 2021 - 2033)
-
Mammalian
-
Non-mammalian
-
-
Service Outlook (Revenue, USD Billion, 2021 - 2033)
-
Process Development
-
Downstream
-
Upstream
-
-
Fill & Finish Operations
-
Analytical & QC studies
-
Packaging & Labelling
-
Others
-
-
Drug Type Outlook (Revenue, USD Billion, 2021 - 2033)
-
Biologics
-
Monoclonal antibodies (mAbs)
-
Recombinant Proteins
-
Vaccines
-
Antisense, RNAi, & Molecular Therapy
-
Others
-
-
Biosimilars
-
-
Type Outlook (Revenue, USD Billion, 2021 - 2033)
-
Drug Substance
-
Finished Drug Product
-
-
Scale of Operation Outlook (Revenue, USD Billion, 2021 - 2033)
-
Clinical
-
Commercial
-
-
Therapeutic Area Outlook (Revenue, USD Billion, 2021 - 2033)
-
Oncology
-
Autoimmune Diseases
-
Infectious Diseases
-
Cardiovascular Diseases
-
Metabolic Diseases
-
Neurology
-
Others
-
-
Regional Outlook (Revenue, USD Billion, 2021 - 2033)
-
North America
-
U.S.
-
Canada
-
Mexico
-
-
Europe
-
UK
-
Germany
-
France
-
Italy
-
Spain
-
Denmark
-
Sweden
-
Norway
-
-
Asia Pacific
-
Japan
-
China
-
India
-
Australia
-
Thailand
-
South Korea
-
-
Latin America
-
Brazil
-
Argentina
-
-
Middle East & Africa
-
South Africa
-
UAE
-
Saudi Arabia
-
Kuwait
-
Qatar
-
Oman
-
-
Research Methodology
The biopharmaceuticals contract manufacturing market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing-reconciling supply-side and demand-side estimates-and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each biopharmaceuticals contract manufacturing segment quantified using the revenue-capture definitions in the table below.
Segment Definition
Segment - Service
Revenue Capture Definition
Bioanalytical Testing
The segment captures revenue generated from bioanalytical testing services provided for pharmaceutical and biopharmaceutical products throughout preclinical and clinical development. Services include pharmacokinetic and pharmacodynamic analysis, biomarker quantification, immunogenicity assessment, ligand binding assays, and bioanalytical method validation.
Clinical
The segment captures revenue generated from bioanalytical testing services conducted to support clinical trials. Services include analysis of clinical samples, pharmacokinetic studies, biomarker testing, immunogenicity assessment, therapeutic drug monitoring, and regulatory-compliant bioanalysis across Phase I to Phase IV clinical studies.
Non-Clinical
The segment captures revenue generated from bioanalytical testing services supporting nonclinical drug development. Services include toxicokinetic analysis, pharmacokinetic evaluation, biomarker studies, bioanalytical method development, and sample analysis for animal studies conducted prior to clinical evaluation.
Method Development & Validation
The segment captures revenue generated from analytical method development and validation services for pharmaceutical products. Services include method optimization, validation of analytical procedures, method transfer, robustness studies, accuracy and precision assessment, and regulatory documentation supporting product development and commercial manufacturing.
Extractable & Leachable
The segment captures revenue generated from extractables and leachables testing services performed to identify and quantify chemical compounds released from packaging materials, delivery systems, manufacturing equipment, and container closure systems that may affect pharmaceutical product quality and patient safety.
Impurity Method
The segment captures revenue generated from impurity method development and analytical testing services used to detect, identify, quantify, and characterize process related impurities, degradation products, residual solvents, elemental impurities, and other contaminants in pharmaceutical products in accordance with regulatory requirements.
Technical Consulting
The segment captures revenue generated from technical consulting services supporting pharmaceutical analytical testing. Services include analytical strategy development, laboratory investigations, regulatory consulting, method troubleshooting, quality system support, data review, and compliance guidance throughout pharmaceutical development and manufacturing.
Others (Method Development & Validation)
The segment captures revenue generated from other analytical method development and validation services, including analytical feasibility studies, technology transfer support, cleaning validation methods, dissolution method development, and customized analytical solutions not classified under other service categories.
Stability Testing
The segment captures revenue generated from stability testing services performed to evaluate the physical, chemical, microbiological, and biological stability of pharmaceutical products under defined storage conditions. Services support shelf life determination, storage condition evaluation, and regulatory submissions throughout product development and commercialization.
Drug Substance
The segment captures revenue generated from stability testing services performed on active pharmaceutical ingredients and drug substances. Services include long term, accelerated, stress, and intermediate stability studies to evaluate product integrity, degradation profiles, and compliance with regulatory stability requirements.
Stability Indicating Method Validation
The segment captures revenue generated from validation of stability-indicating analytical methods capable of accurately detecting changes in pharmaceutical products during stability studies. Services ensure analytical methods can distinguish active ingredients from degradation products and impurities under regulatory guidelines.
Accelerated Stability Testing
The segment captures revenue generated from accelerated stability testing services conducted under elevated temperature and humidity conditions to predict product shelf life, evaluate degradation pathways, and support regulatory submissions within shorter development timelines.
Photostability Testing
The segment captures revenue generated from photostability testing services performed to evaluate the effects of light exposure on pharmaceutical products. Services determine product stability under controlled light conditions in accordance with regulatory guidelines and support packaging selection and labeling requirements.
Others (Stability Testing)
The segment captures revenue generated from other stability testing services, including in use stability studies, freeze thaw stability studies, shipping stability assessments, container closure stability evaluation, and customized stability protocols developed to meet specific product requirements.
Others (Service)
The segment captures revenue generated from other pharmaceutical analytical testing services, including microbiological testing, environmental monitoring, batch release testing, raw material testing, dissolution testing, particulate analysis, elemental impurity testing, cleaning validation, and quality control services not included within the above service categories.
Segment - End Use
Revenue Capture Definition
Pharmaceutical Companies
The segment captures revenue generated from pharmaceutical companies outsourcing analytical testing services for small molecule drugs and specialty pharmaceutical products. Services include bioanalytical testing, method development and validation, stability studies, quality control testing, impurity analysis, and regulatory support across the drug development lifecycle.
Biopharmaceutical Companies
The segment captures revenue generated from biopharmaceutical companies outsourcing analytical testing services for biologics, biosimilars, monoclonal antibodies, recombinant proteins, vaccines, cell therapies, and gene therapies. Services include bioanalytical characterization, immunogenicity testing, biomarker analysis, stability testing, and analytical method validation supporting product development and commercialization.
Others
The segment captures revenue generated from analytical testing services provided to other end users, including contract development and manufacturing organizations, academic and research institutions, government laboratories, medical device manufacturers, and emerging biotechnology companies requiring specialized analytical support, quality testing, and regulatory compliance services.
Segment - Source
Revenue Capture Definition
Mammalian
The segment captures revenue generated by contract manufacturing services provided using mammalian cell expression systems, including Chinese hamster ovary (CHO), HEK293, and NS0 cells, for the production of monoclonal antibodies, recombinant proteins, and other complex biologics. Services include cell line development, process development, upstream and downstream manufacturing, analytical testing, and commercial production.
Non mammalian
The segment captures revenue generated by contract manufacturing services provided using non mammalian expression systems, including microbial, yeast, insect, and other cell platforms, for the production of recombinant proteins, enzymes, plasmid DNA, vaccines, peptides, and other biologic products. Services include fermentation, purification, analytical testing, scale-up, and commercial manufacturing.
Segment - Service
Revenue Capture Definition
Process Development
The segment captures revenue generated from process development services for biologic products. Services include cell line optimization, process characterization, scale-up studies, manufacturing process optimization, technology transfer, and process validation to support clinical and commercial biologics manufacturing.
Downstream
The segment captures revenue generated from downstream processing services involved in the purification and recovery of biologic products. Services include chromatography, filtration, viral clearance, concentration, polishing, and purification processes required to achieve product quality and regulatory compliance.
Upstream
The segment captures revenue generated from upstream manufacturing services involving cell culture, microbial fermentation, media preparation, seed train development, bioreactor operations, and biologic production prior to purification.
Fill and Finish Operations
The segment captures revenue generated from aseptic fill and finish services for biologic drug products. Services include formulation, sterile filling, vial, syringe and cartridge filling, lyophilization, visual inspection, packaging preparation, and commercial drug product manufacturing.
Analytical and QC Studies
The segment captures revenue generated from analytical testing and quality control services supporting biologics development and manufacturing. Services include product characterization, method development, stability testing, impurity analysis, release testing, comparability studies, and quality assurance activities.
Packaging and Labelling
The segment captures revenue generated from packaging and labelling services for biologic drug products. Services include primary and secondary packaging, serialization, labelling, inspection, and packaging operations supporting regulatory compliant commercial distribution.
Others
The segment captures revenue generated from additional contract manufacturing services, including formulation development, technology transfer, regulatory support, warehousing, cold chain management, supply chain support, and other specialized manufacturing activities not included in the above categories.
Segment - Drug Type
Revenue Capture Definition
Biologics
The segment captures revenue generated by contract manufacturing services provided for biologic therapeutics, including monoclonal antibodies, recombinant proteins, vaccines, oligonucleotide therapies, and other biologic products. Services include development, manufacturing, analytical testing, fill and finish, and commercial production.
Monoclonal Antibodies (mAbs)
The segment captures revenue generated by contract manufacturing services provided for monoclonal antibody therapeutics. Services include cell line development, upstream and downstream processing, analytical characterization, fill and finish, and commercial manufacturing for therapeutic antibodies.
Recombinant Proteins
The segment captures revenue generated by contract manufacturing services provided for recombinant protein therapeutics. Services include expression system development, protein production, purification, analytical testing, formulation, and commercial manufacturing.
Vaccines
The segment captures revenue generated by contract manufacturing services provided for preventive and therapeutic vaccines. Services include antigen production, fermentation or cell culture manufacturing, purification, formulation, aseptic filling, analytical testing, and commercial production.
Antisense, RNAi, and Molecular Therapy
The segment captures revenue generated by contract manufacturing services provided for antisense oligonucleotides, RNA interference therapeutics, and other molecular therapies. Services include process development, manufacturing, purification, analytical testing, formulation, and commercial production.
Others
The segment captures revenue generated by contract manufacturing services provided for other biologic products not classified under the specified categories, including cytokines, growth factors, enzymes, fusion proteins, and novel biologic modalities.
Biosimilars
The segment captures revenue generated by contract manufacturing services provided for biosimilar products. Services include process development, analytical comparability studies, manufacturing, validation, fill and finish, and commercial production supporting biosimilar commercialization.
Segment - Type
Revenue Capture Definition
Drug Substance
The segment captures revenue generated from contract manufacturing of biologic drug substances. Services include cell culture or fermentation, upstream and downstream processing, purification, process validation, analytical testing, and bulk biologic production.
Finished Drug Product
The segment captures revenue generated from contract manufacturing of finished biologic drug products. Services include formulation, aseptic fill and finish, packaging, labeling, quality control, and commercial product release.
Segment - Scale of Operation
Revenue Capture Definition
Clinical
The segment captures revenue generated from contract manufacturing services supporting clinical-stage biologic products. Services include process development, clinical batch manufacturing, analytical testing, regulatory documentation, and manufacturing for Phase I, Phase II, and Phase III clinical trials.
Commercial
The segment captures revenue generated from commercial-scale contract manufacturing services for approved biologic products. Services include large-scale manufacturing, process validation, quality control, commercial fill and finish, packaging, and ongoing commercial supply.
Segment - Therapeutic Area
Revenue Capture Definition
Oncology
The segment captures revenue generated by contract manufacturing services provided for biologic therapies used in the treatment of cancer. Services include manufacturing of monoclonal antibodies, antibody drug conjugates, recombinant proteins, immunotherapies, analytical testing, and commercial production.
Autoimmune Diseases
The segment captures revenue generated by contract manufacturing services provided for biologic therapies used in the treatment of autoimmune and inflammatory disorders. Services include process development, biologics manufacturing, analytical testing, formulation, and commercial production.
Infectious Diseases
The segment captures revenue generated by contract manufacturing services provided for biologic products used in the prevention and treatment of infectious diseases. Services include vaccine manufacturing, recombinant protein production, analytical testing, fill and finish, and commercial manufacturing.
Cardiovascular Diseases
The segment captures revenue generated by contract manufacturing services provided for biologic therapeutics targeting cardiovascular diseases. Services include process development, biologics manufacturing, quality testing, formulation, and commercial production.
Metabolic Diseases
The segment captures revenue generated by contract manufacturing services provided for biologic therapies used in the treatment of metabolic disorders, including diabetes and related conditions. Services include biologics manufacturing, analytical testing, formulation, and commercial production.
Neurology
The segment captures revenue generated by contract manufacturing services provided for biologic therapeutics used in the treatment of neurological disorders. Services include process development, biologics manufacturing, analytical testing, fill and finish, and commercial production.
Others
The segment captures revenue generated by contract manufacturing services provided for biologic products used in therapeutic areas not covered above, including respiratory diseases, ophthalmology, dermatology, hematology, rare diseases, and other specialty indications.
To learn more about this report, Download Free Sample Report Delivered Customizations
This report has been delivered with the following In-depth customizations
Client Request
Customization Delivered
Value Adds
Industry Outlook, Value Chain, and Business Model Assessment
Conducted a comprehensive assessment of the biopharmaceutical contract manufacturing ecosystem, covering cell line development providers, media and raw material suppliers, upstream and downstream processing partners, analytical testing laboratories, drug substance manufacturers, fill and finish service providers, packaging companies, cold chain logistics providers, and pharmaceutical and biotechnology companies. Assessed prevailing business models, outsourcing trends, revenue streams, pricing structures, supply chain dependencies, and value creation opportunities across process development, clinical manufacturing, commercial manufacturing, technology transfer, and integrated CDMO services.
Provides a comprehensive understanding of the biopharmaceutical contract manufacturing value chain, outsourcing trends, revenue generation models, and operational dependencies, enabling stakeholders to identify growth opportunities, optimize outsourcing strategies, and support informed investment and expansion decisions.
Competitive Benchmarking and Manufacturing Capability Analysis
Performed detailed benchmarking of leading biopharmaceutical contract manufacturers based on biologics manufacturing capacity, mammalian and non mammalian expression platforms, upstream and downstream processing capabilities, analytical testing expertise, fill and finish capabilities, regulatory compliance, geographic footprint, technology platforms, integrated service offerings, and strategic partnerships. Included comparative positioning of global CDMOs supporting monoclonal antibodies, recombinant proteins, vaccines, biosimilars, and other biologic products.
Enables identification of competitive strengths, manufacturing capability gaps, partnership opportunities, acquisition prospects, and technology differentiation, supporting strategic planning, capacity expansion decisions, and long-term competitive positioning within the global biopharmaceutical contract manufacturing market.
Global Regulatory Landscape and Compliance Assessment
Conducted a comprehensive assessment of regulatory requirements governing biopharmaceutical contract manufacturing across North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The analysis covered current Good Manufacturing Practice requirements, biologics manufacturing standards, process validation, sterility assurance, quality management systems, facility inspection trends, and regulatory expectations established by major global health authorities. The assessment also evaluated regional regulatory differences and their impact on manufacturing operations, technology transfer, and outsourcing strategies.
Enables manufacturers, pharmaceutical companies, and investors to understand evolving regulatory requirements, reduce compliance risks, strengthen quality systems, support successful facility inspections, and develop market entry and expansion strategies aligned with regional regulatory frameworks.
Frequently Asked Questions About This Report
North America dominated with a 34.6% revenue share in 2025.
Asia Pacific is the fastest-growing region over the forecast period.
The biologics segment led with a 78.1% revenue share in 2025, while biosimilars segment is fastest growing drug type.
The oncology segment held the largest revenue share of 38.3% in 2025, while autoimmune diseases segment is fastest growing therapeutic area.
Based on service, the process development segment led with a 34.7% revenue share in 2025.
The global biopharmaceuticals contract manufacturing market size was valued at USD 44.7 billion in 2025 and is estimated at USD 50.0 billion in 2026.
The global biopharmaceuticals contract manufacturing market is expected to grow at a CAGR of 10.5% from 2026 to 2033, reaching USD 100.8 billion by 2033.
Key players include Boehringer Ingelheim GmbH; Lonza; Inno Biologics Sdn Bhd; Rentschler Biotechnologie GmbH; JRS Pharma; AGC Biologics; ProBioGen; Fujifilm Diosynth Biotechnologies U.S.A.; Inc.; Toyobo Co.; Ltd.; Samsung BioLogics; Thermo Fisher Scientific, Inc.; Binex Co., Ltd.; WuXi Biologics; AbbVie, Inc; Novartis AG; ADMA Biologics, Inc.; Catalent, Inc; Cambrex Corporation; Pfizer Inc.; Siegfried Holding AG, among others.
Key factors include expanding biologics pipelines, increased outsourcing by pharmaceutical and biotechnology companies, rising demand for monoclonal antibodies and biosimilars, growing commercial manufacturing requirements for biologics, and ongoing investments in global biopharmaceutical manufacturing capacity. The market growth is further supported by the increasing complexity of biologic manufacturing processes, stringent regulatory requirements, and the need for specialized production technologies that require substantial capital investment.
About the Author(s)
Biotechnology Research Team
Healthcare · BiotechnologyThis report was authored by the biotechnology research team at Grand View Research - comprising two research analysts, one senior research analyst, and one industry expert - with specialized expertise in the biotechnology segment of the healthcare industry. All findings are based on proprietary healthcare databases, executive interviews, and regulatory analysis, subject to internal peer review prior to publication.
Last Updated:
Speak to Analyst
Customize this report to your needs - add regions, segments, or data points, with 20% free customization.
Or view our licence options:
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
